Trials / Recruiting
RecruitingNCT06381349
Predicting Outcomes of GPOEM Using Gastric Electrical Mapping
Predicting Outcomes of Gastric Peroral Endoscopic Myotomy Using a Gastric Electrical Mapping System: GPOEM-GEMS
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 300 (estimated)
- Sponsor
- Chris Varghese · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Gastric peroral endoscopic myotomy (GPOEM) is a minimally-invasive procedure that involves dividing the pylorus, to enhance gastric emptying in gastroparesis patients. This is a single-arm, multi-centre, prospective observational study to determine the clinical utility of Gastric Alimetry in predicting GPOEM treatment outcomes. The investigators further aim to develop a clinical decision rule to inform patient selection. Gastric Alimetry will be conducted \<1 month prior to GPOEM. All subjects will then be followed up for 12 months.
Detailed description
This protocol proposes no change to the clinical management of patients which is left to the discretion of the patients' primary clinical team. Patients as part of this study will undergo a baseline assessment via Gastric Alimetry, and concurrent symptom, quality of life, and health psychology questions. GPOEM will be performed as per standard site protocol, with data captured in RDCap. Patients will be followed up at 1-month, 3-month, 6-months, and 12-months using the myCap (REDCap) app. Participants and clinicians can opt-in for a repeat Gastric Alimetry test at 6 or 12 months following their GPOEM procedure.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Gastric Alimetry test | Gastric Alimetry test will be performed within 30-days prior to G-POEM procedure. It's results will not inform clinical management in this observational study. |
Timeline
- Start date
- 2024-07-07
- Primary completion
- 2026-05-01
- Completion
- 2026-06-01
- First posted
- 2024-04-24
- Last updated
- 2025-03-27
Locations
1 site across 1 country: New Zealand
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT06381349. Inclusion in this directory is not an endorsement.